Innate Pharma S.A. (EPA:IPH)

France flag France · Delayed Price · Currency is EUR
1.804
+0.086 (5.01%)
Apr 23, 2025, 5:35 PM CET
-16.87%
Market Cap 151.20M
Revenue (ttm) 20.12M
Net Income (ttm) -49.47M
Shares Out 83.81M
EPS (ttm) -0.61
PE Ratio n/a
Forward PE 2.44
Dividend n/a
Ex-Dividend Date n/a
Volume 336,570
Average Volume 112,130
Open 1.810
Previous Close 1.718
Day's Range 1.742 - 1.858
52-Week Range 1.330 - 2.790
Beta 0.95
RSI 47.16
Earnings Date Mar 27, 2025

About Innate Pharma

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 181
Stock Exchange Euronext Paris
Ticker Symbol IPH
Full Company Profile

Financial Performance

In 2024, Innate Pharma's revenue was 20.12 million, a decrease of -67.36% compared to the previous year's 61.64 million. Losses were -49.47 million, 553.5% more than in 2023.

Financial Statements

News

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announce review of their January 2016 Research Coll...

1 day ago - Business Wire

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma proposes to its shareholders to transform its corporate governance structure into a board of directors and to change its composition.

8 days ago - Business Wire

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to hold its Annual General Meeting of shareholders on May 22, 2025.

8 days ago - Business Wire

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in the 2025 Stifel Virtual Targeted Oncology Forum.

21 days ago - Business Wire

Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2024 Earnings Conference Call March 27, 2025 9:00 AM ETCompany ParticipantsHenry Wheeler - VP, IR and...

27 days ago - Seeking Alpha

Innate Pharma S.A. 2024 Q4 - Results - Earnings Call Presentation

The following slide deck was published by Innate Pharma S.A.

27 days ago - Seeking Alpha

Innate Pharma reports FY results

27 days ago - Seeking Alpha

Innate Pharma Reports Full Year 2024 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the y...

4 weeks ago - Business Wire

Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting

MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH4502, its nov...

4 weeks ago - Business Wire

Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference.

4 weeks ago - Business Wire

Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for full year 2024 financial results.

5 weeks ago - Business Wire

Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in The 2025 Leerink Partners Global Healthcare Conference.

2 months ago - Business Wire

Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion

Positive results achieved in the open-label phase 2 TELLOMAK study, using lacutamab for the treatment of patients with relapsed/refractory Sezary Syndrome; Patients achieved a confirmed Objective Resp...

2 months ago - Seeking Alpha

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary Syndrome.

2 months ago - Business Wire

Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket

Shares of Logility Supply Chain Solutions, Inc . (NASDAQ: LGTY) rose sharply in today's pre-market trading after Aptean announced an agreement to acquire Logility in a $14.30-per-share all-cash deal ...

3 months ago - Benzinga

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its P...

3 months ago - Business Wire

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces Nectin-4 antibody drug conjugate investor and analyst event in New York.

3 months ago - Business Wire

Innate Pharma Announces Transformative Strategy to Accelerate Growth

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its updated strategy for company growth. ...

3 months ago - Business Wire

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that its management will present and host...

4 months ago - Business Wire

Innate Pharma presents lacutamab improved health-related quality of life data at ASH 2024

New data from Innate Pharma SA highlights quality-of-life improvements in patients with cutaneous T-cell lymphoma treated with lacutamab in the TELLOMAK...

4 months ago - Seeking Alpha

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced new data highlighting the quality-of-life...

4 months ago - Business Wire

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

MARSEILLE, France & DIAMOND BAR, Calif.--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), together with the Institute for Fo...

4 months ago - Business Wire

Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that abstracts related to lacutamab healt...

5 months ago - Business Wire